Xiaochun Zheng

Hangzhou, 310014, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy.

Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy.

Journal: Molecular pharmaceutics
Published: September 26, 2025

Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China.

Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China.

Journal: PloS one
Published: March 11, 2025

Post-Marketing Safety Concerns with Efgartigimod alfa: A Pharmacovigilance Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database.

Post-Marketing Safety Concerns with Efgartigimod alfa: A Pharmacovigilance Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database.

Journal: Clinical epidemiology
Published: December 28, 2024

Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database.

Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database.

Journal: BMJ open
Published: October 17, 2024

Cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer.

Cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer.

Journal: Future oncology (London, England)
Published: September 20, 2024

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.

Journal: Scientific reports
Published: September 05, 2024

Pulmonary adverse reaction caused by furazolidone: Two case reports and a literature review.

Pulmonary adverse reaction caused by furazolidone: Two case reports and a literature review.

Journal: Medicine
Published: August 16, 2024

A real-world pharmacovigilance study of modafinil events in the FDA Adverse Event Reporting System (FAERS).

A real-world pharmacovigilance study of modafinil events in the FDA Adverse Event Reporting System (FAERS).

Journal: Journal of affective disorders
Published: August 16, 2024

Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database.

Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database.

Journal: Clinical epidemiology
Published: May 27, 2024

Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma.

Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma.

Journal: Scientific reports
Published: May 09, 2024

Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.

Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.

Journal: Journal of medicinal chemistry
Published: May 09, 2024

Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.

Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.

Journal: BMC cancer
Published: January 06, 2024
Showing 1-12 of 22

Last Updated: 09/26/2026